Randox Laboratories’ newly-launched biochemistry Adiponectin assay has achieved CE approval.
Testing adiponectin allows assessment of the risk of developing Type 2 diabetes and Cardiovascular Disease (CVD).
Adiponectin is a protein hormone produced and secreted exclusively by adipocytes. It regulates the metabolism of lipids and glucose, and influences the body’s response to insulin.
Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels.
Low levels of adiponectin therefore can be indicative of insulin resistance (leading to type 2 diabetes), and Cardiovascular Disease (CVD).
Low adiponectin levels have also been shown to correlate with increased likelihood of a woman developing gestational diabetes in pregnancy.
Randox also offers two levels of adiponectin controls as well as an adiponectin calibrator, delivering a complete testing package.